Neuron23 Alternatives & Competitors
12 companies similar to Neuron23 — Combining cutting-edge science, human genetics, and a patient-centered approach...
Companies similar to Neuron23
Satori Pharmaceuticals
Pioneering advanced therapies for Alzheimer's, Parkinson's, and other neurodegenerative di...
Annovis Bio, Inc.
Transforming how we treat Alzheimer’s, Parkinson’s, and beyond.
Malvern, United States
ESCAPE Bio
A CLINICAL-STAGE COMPANY DEVELOPING NOVEL, PRECISELY TARGETED THERAPIES FOR GENETIC NEUROD...
South San Francisco, Unit...
Track all Neuron23 competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
AXON Neuroscience
Independent clinical stage biotech company.
Bratislava, Slovakia
Drug Farm
Drug Farm is a US and China-based biotech specialized in first-in-class drug development f...
Shanghai, China
Gain Therapeutics
Unfolding the next generation of allosteric small molecule therapies to meet patient needs...
Bethesda, United States
Wren Therapeutics
Stopping the wave of neurodegeneration at its source
Cambridge, United Kingdom
Allyx Therapeutics
Protecting Synapses and Reversing Neurodegeneration
New Haven, United States
AC Immune
Shifting the treatment paradigm for neurodegenerative disease towards precision medicine a...
Lausanne, Switzerland
T3D Therapeutics, Inc.
Developing a potentially disease-modifying, new drug treatment for Alzheimer’s and other n...
Durham, United States
About Neuron23
Neuron23, founded in 2018, is a clinical-stage biotechnology company based in the United States. The company is pioneering advancements in precision medicine, specifically targeting Parkinson’s disease driven by hyperactive LRRK2. By integrating cutting-edge science with human genetics and its proprietary drug discover...
Development of precision medicine for Parkinson's Disease, Clinical trials for novel therapeutic approaches, Research and development in neuroimmunology and neuroscience
Patients with Parkinson's Disease, Healthcare providers specializing in neurology, Pharmaceutical and biotechnology investors
Precision Medicine, Parkinson's Disease, Neurodegenerative Diseases, Human Genetics, Biomarker Platform, Drug Discovery, Neurological Diseases, Alzheimer's Disease, Clinical-stage Biotechnology, Hyperactive LRRK2, Patient-centered Approach, Neuroinflammatory Diseases, Autoimmune Diseases
B2B, B2D, D2C
Licensing, Performance Based, Product Sales
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches Neuron23 and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at Neuron23 on 31 Mar 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
